-
-
Vitamin D status in newborns and long-term neuropsychiatric outcomes Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-14 Isabel Gamache, Wiame Belbellaj, Basile Jumentier, Despoina Manousaki
No Abstract
-
Advancing clinical trials for anxiety disorders in older adults Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-14 Carly J Johnco
No Abstract
-
Adolescent mental health measures Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-14 Laura Duncan, R Christopher Sheldrick
No Abstract
-
Awais Aftab: a multidimensional approach to psychiatry Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-14 Talha Burki
No Abstract
-
Convergent evidence linking neonatal vitamin D status and risk of neurodevelopmental disorders: a Danish case-cohort study Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-14 Henriette Thisted Horsdal, Clara Albiñana, Zhihong Zhu, Sanne Grundvad Boelt, Nis Borbye-Lorenzen, Arieh S Cohen, Kristin Skogstrand, Lars Melgaard, Nadia Jensen MacSween, Marta Jadwiga Thorbek, Oleguer Plana-Ripoll, Liselotte Vogdrup Petersen, Cynthia M Bulik, Anders D B⊘rglum, Ole Mors, Merete Nordentoft, Thomas Werge, Gunn-Helen Moen, Shannon D’Urso, Naomi R Wray, John J McGrath
BackgroundThere is growing evidence linking neonatal vitamin D deficiency to an increased risk of schizophrenia, ADHD, and autism spectrum disorder (ASD). The aim of this study was to examine the association between two vitamin D biomarkers (25 hydroxyvitamin D [25(OH)D] and vitamin D-binding protein [DBP], and their related genetic correlates) and the risk of six mental disorders. MethodsWe used a
-
Pharmacological treatment of anxiety in older adults: a systematic review and meta-analysis Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-14 Sarah E Neil-Sztramko, AnneMarie Levy, Alastair J Flint, Zahra Goodarzi, Amy Gough, Shanna C Trenaman, Michael Van Ameringen, Erica Weir, Anthony Yeung, Mahnoor R Akram, Titus A Chan, Sébastien Grenier, Heli Juola, Juliette Mojgani, Kristin Reynolds, Carly Whitmore, Andrea Iaboni
BackgroundAnxiety and its disorders are common in later life. Given the known risks of psychopharmacological treatments in older adults, clinical decision making for anxiety management should be guided by the strongest available evidence. This study aimed to comprehensively synthesise evidence on the pharmacological treatment of anxiety in older adults. MethodsIn this systematic review and meta-analysis
-
Mindfulness-based cognitive therapy versus treatment as usual after non-remission with NHS Talking Therapies high-intensity psychological therapy for depression: a UK-based clinical effectiveness and cost-effectiveness randomised, controlled, superiority trial Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-14 Thorsten Barnhofer, Barnaby D Dunn, Clara Strauss, Florian A Ruths, Barbara Barrett, Mary Ryan, Asha Ladwa, Frances Stafford, Roberta Fichera, Hannah Baber, Ailis McGuinness, Isabella Metcalfe, Daniel K Y Kan, Joanna Pooley, Delilah Harding, Emma Tassie, James Carson, Shelley Rhodes, Allan H Young, James Connors, Fiona C Warren
BackgroundNon-remission after psychological therapy for major depressive disorder is common, yet there are no established further-line treatments. In the UK National Health Service (NHS) Talking Therapies programme, about 50% of patients with depression who come to the end of the stepped care pathway do not show remission of symptoms. We aimed to investigate whether mindfulness-based cognitive therapy
-
Correction to Lancet Psychiatry 2025; 12: 266–75 Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-08
Nomura N, Siafis S, Schneider-Thoma J, et al. The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials inacute phase schizophrenia. Lancet Psychiatry 2025; 12: 266–75—The appendix of this Article has been corrected as of May 8, 2025.
-
Reproductive rights of women with severe mental disability and rights of their children in China Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-08 Yang Zhang, Xingbo Suo, Jin Gao
No Abstract
-
Recovery-oriented psychiatry: oxymoron or catalyst for change? Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-06 Helene Speyer, David Roe, Mike Slade
This Personal View provides a normative and conceptual analysis of the intersection between the recovery movement and psychiatry. Although recovery emerged as a grassroots social justice movement emphasising empowerment and systemic change, psychiatry remains rooted in the medical paradigm. We aim to develop a nuanced conceptual framework that fosters academic debate and meaningful implementation,
-
Association between genetic liability to physical health conditions and comorbidities in individuals with severe mental illness: an analysis of two cross-sectional observational studies in the UK Lancet Psychiatry (IF 30.8) Pub Date : 2025-05-05 Djenifer B Kappel, Sophie E Smart, Michael J Owen, Michael C O'Donovan, Antonio F Pardiñas, James T R Walters
BackgroundIndividuals with severe mental illness, including schizophrenia and bipolar disorder, have elevated rates of physical health conditions, contributing to increased morbidity and mortality. While environmental factors such as adverse effects from medication and lifestyle changes play a role, the contribution of genetic liability to physical health comorbidities remains underexplored. We investigated
-
Correction to Lancet Psychiatry 2025; 12: 276–88 Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-29
Cleare AJ, Kerr-Gaffney J, Goldsmith K, et al. Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK. Lancet Psychiatry 2025; 12: 276–88—In this Article, Kirsty James should have been included in the LQD Study Group list. This correction has been made to
-
Correction to Lancet Psychiatry 2025; published online April 23. https://doi.org/10.1016/S2215-0366(25)00096-3 Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-29
Mimiaga MJ, Yonko EA. LGBTQ+ mental health in the wake of USA politics. Lancet Psychiatry 2025; published online April 23. https://doi.org/10.1016/S2215-0366(25)00096-3—The fourth sentence of paragraph 2 should read, “data from the 2015 US transgender survey found that 7% had attempted suicide in the past year,4 almost 12 times the rate in the USA population (0·6%) as reported by the Substance Abuse
-
Correction to Lancet Psychiatry 2025; 12: 384–94 Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-28
McCutcheon RA, Pillinger T, Varvari I, et al. INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia. Lancet Psychiatry 2025; 12: 384–94—In this Health Policy, an arrow in the figure erroneously pointed from the Assess Adherence box to Effective?. This correction has been made to the online version as of MMM DD, YYYY
-
A novel discovery platform for targeted drug repurposing: application for psychiatric disorders Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-23 Michael Berk, Jee Hyun Kim, Lana J Williams, Zoe S J Liu, Dan Siskind, Bruna Panizzutti, Alison R Yung, Ken Walder
Existing pharmacotherapies and psychotherapies are often inadequate, and discovery for new pharmacological treatments in psychiatry is slow. Existing pharmacotherapies are, however, often inadequate. Few truly novel pharmacotherapies have emerged in the past four decades, largely due to the absence of a known pathophysiology for each disorder. In this Personal View, we describe the platform we have
-
Improving mental health care in Iran Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-24 Rahim Badrfam, Atefeh Zandifar
No Abstract
-
Bridging gaps in autism spectrum disorder care Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-24 Ajeng Ayu Widiastuti, Adi Atmoko, Nur Eva, Eunike Milasari Listyaningrum, Trivena Dyah Wijayanti
No Abstract
-
LGBTQ+ mental health in the wake of USA politics Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-23 Matthew J Mimiaga, Elizabeth A Yonko
No Abstract
-
Priorities for addressing mental health conditions and substance use disorders in prisons in sub-Saharan Africa: expert consensus from a Delphi panel Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Helen E Jack, Aish Lovett, Hiwot Weldemariam, Atalay Alem, Serge Dali, Sakios Muduma, Murugi Micheni, Letitia Pienaar, Charlene Sunkel, Zoë Senter, Maryia Shaban, Lydia Chwastiak, Sarah Walker, Adegboyega Ogunwale
People who are incarcerated in Africa are not a focus of global mental health research, and incarceration is absent from many international mental health guidelines. Given the dearth of knowledge and services, priorities for research and practice should be established. The Delphi method was used to identify priority challenges related to mental health and substance use disorders among people who are
-
Setting the research agenda for mental health Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 The Lancet Psychiatry
No Abstract
-
Priovi appears to be a valuable digital tool for patients with borderline personality disorder Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Vivian B Pender
No Abstract
-
Accurate prevalence estimates needed for youth common mental disorders Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Patrick D McGorry, Eóin Killackey, Eric Chen, Andrew Chanen
No Abstract
-
Accurate prevalence estimates needed for youth common mental disorders – Authors' reply Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Ellie M Robson, Susan M Sawyer, Article coauthors
No Abstract
-
Does ADHD treatment inefficacy question its diagnostic validity? Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Gin S Malhi, Kinga Szymaniak, Erica Bell
No Abstract
-
Does ADHD treatment inefficacy question its diagnostic validity? – Authors' reply Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Edoardo G Ostinelli, Andrea Cipriani, Samuele Cortese
No Abstract
-
Bipolar depression management needs randomised controlled trial evidence Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Chien Cheng, Tien-Wei Hsu, Yu-Chen Kao, Mu-Hong Chen, Chih-Sung Liang
No Abstract
-
Bipolar depression management needs randomised controlled trial evidence – Authors' reply Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Cagatay Ermis, Heidi Taipale, Jari Tiihonen, all authors of the Article
No Abstract
-
Correction to Lancet Psychiatry 2025; 12: e3–6 Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15
The Lancet Psychiatry. Thanks to our peer reviewers for 2024. The Lancet Psychiatry 2025; 12: e3–6—In this Comment, Ángel Aguilera Martín should have been included in the list of peer reviewers for 2024. This correction has been made to the online version as of April 15, 2025.
-
John M Kane: investigator, collector, and innovator Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Jules Morgan
No Abstract
-
A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-15 Nele Assmann PhD, Prof Gitta Jacob PhD, Anja Schaich PhD, Prof Thomas Berger PhD, Tristan Zindler PhD, Linda Betz PhD, Prof Stefan Borgwardt MD, Prof Arnoud Arntz PhD, Prof Eva Fassbinder MD, Prof Jan Philipp Klein MD
Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we tested the effectiveness and safety of priovi, a digital therapeutic for BPD.
-
Recommendations for defining treatment outcomes in major psychiatric disorders using real-world data Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-10 Elise Koch, Sophie Smart, Guðmundur Einarsson, Anders Kämpe, Lina Jonsson, Maris Alver, Matthew Iveson, Andreas Göteson, Antonio F Pardiñas, Ida E Sønderby, Kevin S O'Connell, Qingqin Li, Yi Lu, Hreinn Stefánsson, Kári Stefánsson, Heather Whalley, Mikael Landén, Michael C O'Donovan, Knut Smerud, Gerard R Dawson, Ole A Andreassen
Although information from real-world data can be used to identify factors that aid treatment choice, there are no guidelines for the use of such data. The aim of this Review is to summarise and evaluate definitions of treatment outcomes for antidepressants, antipsychotics, and mood stabilisers when using real-world data, and to suggest standards for the field. Given that no standards for the use of
-
Factors that affect the resilience of young adults to depression: a systematic review Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-08 Linda Theron, Dov J Stekel, Jan Höltge, Olufunmilayo I Fawole, Diane T Levine, Zainab Mai-Bornu, Kassa Maksudi, Olanrewaju Olaniyan, Caradee Y Wright, Michael Ungar
Depression among young people (aged 18–29 years) transitioning to adulthood is becoming more widespread. Knowing which factors in which systems co-enable resilience to depression is crucial, but there is no comprehensive synthesis of the physiological, psychological, social, economic, institutional, cultural, and environmental system factors associated with no or minimal emerging adult depression,
-
Brexpiprazole for the treatment of adolescent schizophrenia Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-07 Maria Rogdaki
No Abstract
-
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-07 Caroline Ward PhD, Prof Milica Pejović Milovančević MD, Eva Kohegyi MD, Nanco Hefting MSc, Catherine Aurang BA, Dalei Chen PhD, Klaus Groes Larsen PhD, Mary Hobart PhD, Prof Christoph U Correll MD
New treatment options are needed for adolescent schizophrenia, partly due to an unfavourable risk–benefit profile of current options. This trial aimed to evaluate the short-term efficacy and safety of brexpiprazole in adolescents with schizophrenia.
-
Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-06 Luis C Farhat PhD, Alice Lannes MD, Cinzia Del Giovane PhD, Valeria Parlatini PhD, Miguel Garcia-Argibay PhD, Edoardo G Ostinelli MD, Anneka Tomlison PhD, Zheng Chang PhD, Prof Henrik Larsson PhD, Cristiano Fava PhD, François Montastruc PhD, Prof Andrea Cipriani PhD, Prof Alexis Revet PhD, Prof Samuele Cortese PhD
Concerns about the cardiovascular safety of medications used for the treatment of attention-deficit hyperactivity disorder (ADHD) remain. We aimed to compare the effects of pharmacological treatments for ADHD on haemodynamic values and electrocardiogram (ECG) parameters in children, adolescents, and adults.
-
Cardiovascular effects of ADHD medications Lancet Psychiatry (IF 30.8) Pub Date : 2025-04-06 Steven R Pliszka
No Abstract
-
INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-31 Robert A McCutcheon PhD, Toby Pillinger PhD, Ioana Varvari MRCPsych, Sean Halstead MD, Olatunde O Ayinde MS, Nicolás A Crossley PhD, Prof Christoph U Correll MD, Prof Margaret Hahn PhD, Prof Oliver D Howes DM, Prof John M Kane MD, Thomas Kabir PhD, Åsa Konradsson-Geuken PhD, Prof Belinda Lennox DM, Christy Lai Ming Hui PhD, Prof Susan L Rossell PhD, Marco Solmi PhD, Prof Iris E Sommer MD PhD, Heidi
Schizophrenia is a mental illness involving multiple symptom domains and is often associated with substantial physical health comorbidities. Guidelines exist, but these tend to be country-specific and are often missing a concise yet comprehensive algorithmic approach. From May 1, 2023, to Jan 1, 2025, International Guidelines for Algorithmic Treatment (INTEGRATE) authors from all UN regions collaborated
-
India's mental health budget 2025 needs urgent reform Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-27 Sheikh Shoib, Ilham Zaidi, Miyuru Chandradasa, Sujita Kumar Kar, Fahimeh Saeed
No Abstract
-
Reevaluating the brain disease model of addiction Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-25 Chrysanthi Blithikioti, Eiko I Fried, Emiliano Albanese, Matt Field, Ioana A Cristea
The brain disease model of addiction has dominated public and scientific discourse on addiction (termed substance use disorder [SUD] in the DSM-5) over the past 3 decades. The model framed addiction as a chronic and relapsing brain disease caused by structural and functional brain alterations. The purpose of this model was purportedly dual, as both an aetiological theory and a tool to reduce stigma
-
The value of many Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-18 The Lancet Psychiatry
No Abstract
-
Antipsychotics and sedation: from clinical to shared decision making Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-18 Subho Chakrabarti
No Abstract
-
Quetiapine augmentation for treatment-resistant depression Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-18 Hannah K Betcher, Megan N Kummerlowe
No Abstract
-
Colonialism, trauma, and mental health Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-18 Uma Devi Khemraj
No Abstract
-
The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophrenia Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-18 Nobuyuki Nomura MD PhD, Spyridon Siafis MD, Johannes Schneider-Thoma MD, Lasse Brandt MD, Jinyoung Park MS, Orestis Efthimiou PhD, Prof Josef Priller MD, John M Davis MD, Hiroyoshi Takeuchi MD PhD, Prof Stefan Leucht MD
Sedative adverse events are common in patients with schizophrenia undergoing antipsychotic treatment, which affects treatment adherence and the patients’ quality of life. Although tolerance to sedation is believed to develop, robust evidence documenting the timing of sedation onset and resolution remains elusive. To address this gap, we aimed to assess the dynamics of onset and resolution of sedation
-
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-18 Prof Anthony J Cleare PhD, Jess Kerr-Gaffney PhD, Prof Kimberley Goldsmith PhD, Zohra Zenasni MSc, Nahel Yaziji MSc, Huajie Jin PhD, Alessandro Colasanti PhD, Prof John R Geddes MD, Prof David Kessler MD, Prof R Hamish McAllister-Williams PhD, Prof Allan H Young PhD, Alvaro Barrera PhD, Lindsey Marwood PhD, Rachael W Taylor PhD, Helena Tee MSc, LQD Study Group, James Rucker, Ryan Williams, Camilla
Lithium and quetiapine are first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly, and none for longer than 8 weeks. We aimed to assess whether quetiapine augmentation therapy is more clinically effective and cost-effective than lithium for patients with treatment-resistant depression over 12 months.
-
Cost-effectiveness of a group psychological intervention for postnatal depression in British south Asian women: an economic evaluation from the ROSHNI-2 trial Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-17 Akbar Ullah PhD, Farah Lunat MSc, Prof Traolach Brugha MD, Matthias Pierce PhD, Prof Richard Morriss MD, Deepali Sharma PhD, Prof Atif Rahman PhD, Prof Kamaldeep Bhui MD, Prof Peter Bower PhD, Prof Nusrat Husain MD
Minority ethnic groups often face ethnocultural barriers in accessing mental health treatments. The ROSHNI-2 trial compared culturally adapted cognitive behavioural therapy (Positive Health Programme [PHP]) with treatment as usual for postnatal depression in British south Asian women. We aimed to assess the cost-effectiveness of the PHP intervention.
-
Cultural practices within Indigenous Australian communities enhance mental health Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-11 William D R Smith, Rebecca Defina, Caitlin Hitchcock
No Abstract
-
Clinical effectiveness of an online psychoeducational and psychotherapeutic programme for caregivers of children newly diagnosed as autistic: a parallel, assessor-masked, randomised controlled trial in the UK (REACH-ASD) Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-11 Kathy Leadbitter PhD, Sophie Langhorne MSc, Richard Smallman PhD, Petrina Chu MSc, Ceri Ellis PhD, Louisa Harrison MA, Tessa Hutton MSc, Charlotte Butter BSc, Caitlin Goldie MA, Kirsty James MSc, Latha Hackett FRCPsych, Alison Dunkerley FRCPsych, Prof Penny Bee PhD, Gemma Shields MPH, Prof Linda Davies MSc, Prof Richard Emsley PhD, Prof Jonathan Green FRCPsych, REACH-ASD Team
Caregivers of autistic children experience particularly poor levels of mental health and increased caregiving complexities. Proactive post-diagnostic family support is recommended but is inconsistently implemented, largely not evidence based, and does not directly address caregiver mental health. This study aimed to test the clinical effectiveness of the Empower-Autism programme plus treatment as usual
-
Sarah Kline: Better mental health everywhere, for everyone Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-07 Jules Morgan
No Abstract
-
Balancing collective forgetting, remembrance, and change to secure Syria's future Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-04 Kinda Alsamara, Alexander C McFarlane
No Abstract
-
Correction to Lancet Psychiatry 2025; published online Feb 19. https://doi.org/10.1016/S2215-0366(25)00005-7 Lancet Psychiatry (IF 30.8) Pub Date : 2025-03-03
Johnson N E, Malimabe M, Yoon G H, et al. Integration of local realities to address mental health in Africa. Lancet Psychiatry 2025; published online Feb 19. https://doi.org/10.1016/S2215-0366(25)00005-7—In this Comment, the first two institutions in the affiliations section should be listed as: Division of Clinical Epidemiology, Department of Clinical Research, University Hospital of Basel, Basel
-
Clozapine and treatment-resistant schizophrenia: efficacy versus effectiveness Lancet Psychiatry (IF 30.8) Pub Date : 2025-02-26 Dan Siskind, Korinne Northwood, Robert A McCutcheon
No Abstract
-
Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis Lancet Psychiatry (IF 30.8) Pub Date : 2025-02-26 Johannes Schneider-Thoma MD, Tasnim Hamza PhD, Konstantina Chalkou PhD, Spyridon Siafis MD, Shimeng Dong MD, Irene Bighelli PhD, Wulf-Peter Hansen, Elfriede Scheuring MEd, Prof John M Davis MD, Prof Josef Priller MD, Prof Pierre Baumann PhD, Prof Robert Conley MD, Prof Joachim Cordes MD, Prof Deanna Kelly PharmD, Prof Michael Kluge MD, Sanjiv Kumra MD, Prof Shôn Lewis MD, Prof Herbert Y Meltzer MD
Clozapine is recommended by national and international guidelines for people with treatment-resistant schizophrenia. However, available meta-analyses of randomised controlled trials have not shown superior efficacy of clozapine when compared with other second-generation antipsychotics, with heterogeneity identified between the original studies. We aimed to use individual patient data (IPD) to account
-
Embracing dissensus in lived experience research: the power of conflicting experiential knowledge Lancet Psychiatry (IF 30.8) Pub Date : 2025-02-26 Helene Speyer MD PhD, Marte Ustrup MSc
Lived experience is a crucial component in the development of innovative interventions and services in mental health care. To unlock the full potential of this valuable source of knowledge, it is essential to actively cultivate and understand it. A common concern, however, is the variability of perspectives, as individuals with lived experience might express opposing views on some issues. Building
-
Advancing appropriate mental health research for LGBTQ+ people in southeast Asia Lancet Psychiatry (IF 30.8) Pub Date : 2025-02-20 Rowalt Alibudbud
No Abstract
-
Integration of local realities to address mental health in Africa Lancet Psychiatry (IF 30.8) Pub Date : 2025-02-19 Natalie E Johnson, Makamohelo Malimabe, Grace H Yoon, Tom L Osborn, Irene Falgas-Bague, Monica H Swahn
No Abstract
-
Mentalisation-based treatment for antisocial personality disorder: reviving the social contract Lancet Psychiatry (IF 30.8) Pub Date : 2025-02-18 Lois W Choi-Kain
No Abstract
-
Thanks to our peer reviewers for 2024 Lancet Psychiatry (IF 30.8) Pub Date : 2025-02-18 The Lancet Psychiatry
Every year, the editorial team at The Lancet Psychiatry relies on expert advice from hundreds of peer reviewers, for which we are always grateful. Our reviewers provide constructive, helpful guidance, for us as editors and for our authors. Several of our reviewers also bring their expertise as people with lived experience of a mental disorder and we are especially grateful for the insight they offer
-
The most important aims of psychotherapy: to love, to work, and to find meaning Lancet Psychiatry (IF 30.8) Pub Date : 2025-02-18 Orestis Zavlis, Peter Fonagy, Patrick Luyten
No Abstract